1. Home
  2. SKYT vs PHAT Comparison

SKYT vs PHAT Comparison

Compare SKYT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SkyWater Technology Inc.

SKYT

SkyWater Technology Inc.

HOLD

Current Price

$16.36

Market Cap

939.6M

Sector

Technology

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$15.39

Market Cap

942.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKYT
PHAT
Founded
1991
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
939.6M
942.6M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
SKYT
PHAT
Price
$16.36
$15.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
6
Target Price
$19.40
$17.33
AVG Volume (30 Days)
1.6M
785.4K
Earning Date
11-05-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.62
N/A
Revenue
$346,587,000.00
$147,190,000.00
Revenue This Year
$28.48
$218.59
Revenue Next Year
$41.29
$84.38
P/E Ratio
$6.24
N/A
Revenue Growth
0.19
460.30
52 Week Low
$5.67
$2.21
52 Week High
$24.23
$16.45

Technical Indicators

Market Signals
Indicator
SKYT
PHAT
Relative Strength Index (RSI) 46.23 61.22
Support Level $17.78 $14.24
Resistance Level $20.88 $16.45
Average True Range (ATR) 1.39 0.76
MACD -0.03 -0.05
Stochastic Oscillator 31.31 52.79

Price Performance

Historical Comparison
SKYT
PHAT

About SKYT SkyWater Technology Inc.

SkyWater Technology Inc is a U.S.-based, independent, pure-play technology foundry that offers semiconductor development and manufacturing services from its fabrication facilities. In its technology as a service model, it leverages a foundation of proprietary technology, engineering to co-develop process technology intellectual property (IP) with its customers that enable disruptive concepts through its Technology Services for diverse microelectronics (integrated circuits) and related micro- and nanotechnology applications. It focuses on serving diversified, high-growth, end users in numerous vertical markets, including computation, aerospace and defense (A&D), automotive and transportation, bio-health, and industrial.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: